Plerixafor (octahydrochloride) 430 5-dimethyl-1H-pyrrol-2-yl)methylidene]-2

5-dimethyl-1H-pyrrol-2-yl)methylidene]-2

5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate

InChi: InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H

730 nM and 580 nM

Smiles: CC1(C)C2[C@@H](OC(C)=O)C(=O)[C@@]3(C)[C@H]([C@H](OC(=O)C4C=CC=CC=4)[C@]1(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C1C=CC=CC=1)C1C=CC=CC=1)C=2C)[C@@]1(CO[C@@H]1C[C@@H]3O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)OC(C)=O

Plerixafor (octahydrochloride) 430 5-dimethyl-1H-pyrrol-2-yl)methylidene]-2Plerixafor, also known as AMD3100, is a bicyclam with hematopoietic stem cell mobilizing activity. Plerixafor blocks the binding of stromal cell derived factor (SDF 1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Plerixafor was approved by the U. S.